deCODE genetics Announces Second Quarter 2008 Financi... (s coming out of core competence in human...)

deCODE genetics Announces Second Quarter 2008 Financial Results

Date:8/6/2008

s coming out of core competence in human genetics, while maintaining a firm control on costs. As we ramp up our sales efforts in diagnostics and deCODEme(TM), our discovery engine is providing us with a steady stream of intellectual property and content for new tests that leverage the same product development infrastructure. Through small, well-designed pharmacology studies like that we recently completed with DG041, we have been able to sharpen the medical and market potential of our lead drug development programs. This is important as we pursue partnership opportunities, with the goal of reaping significant upside from these programs in major therapeutic areas while managing risk," said Kari Stefansson, CEO of deCODE.

Recent highlights include:

Product Development

-- DG041 for arterial thrombosis. In June, deCODE announced positive topline results from its latest clinical pharmacology study of DG041, the company's first-in-class antagonist of the EP3 receptor for prostaglandin E2, being developed as a next-generation oral anti-platelet therapy for preventing arterial thrombosis without increasing bleeding risk. The prospective, randomized, blinded, crossover study compared the effects on platelet activation and bleeding time of DG041 alone and in combination with the mainstays of current anti-platelet treatment, Plavix(TM) (clopidogrel) and aspirin. The results confirm previous clinical findings that DG041 inhibits platelet aggregation without increasing bleeding time as monotherapy, and further demonstrate that in combination with clopidogrel alone, as well as with clopidogrel and aspirin, DG041 provides additional antiplatelet effect without prolonging bleeding time.

-- Diagnostics: Glaucoma. In the second quarter, the company began offering its fifth DNA-based risk assessment diagnostic, deCODE Glaucoma(TM). The test detects two common single letter variations (SNPs) in the sequence of the human genome discovered by deCODE that appea
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
2. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2007 Financial Results
3. deCODE genetics Announces Third Quarter 2007 Financial Results
4. deCODE Launches deCODEme(TM)
5. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
6. deCODE Discovers Gene Variants that May Help to Distribute the Work of Evolution between Men and Women
7. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
8. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
9. deCODE Genetics Announces Full-year 2007 Financial Results
10. deCODE genetics to Webcast Presentation at Lehman Brothers Eleventh Annual Global Healthcare Conference
11. deCODE genetics to Webcast Presentation at 15th Annual Future Leaders in the Biotech Industry Conference

Post Your Comments:

deCODE genetics Announces Second Quarter 2008 Financi...(s coming out of core competence in human...)